Retatrutide's diabetes data heads to ADA 2026
Lilly will present Phase 3 retatrutide results at ADA's June 5–8 meeting, including TRANSCEND-T2D-1 — a 2.0% A1C drop and 16.8% weight loss in type 2 diabetes.
June 1, 2026 · 3 min read
Eli Lilly said on May 28, 2026 that it will present detailed Phase 3 results for retatrutide — its investigational once-weekly GIP, GLP-1, and glucagon triple receptor agonist — at the American Diabetes Association's 86th Scientific Sessions, running June 5–8 in New Orleans. The headline-grabber so far has been the obesity data, but the meeting also brings the first detailed look at TRANSCEND-T2D-1, retatrutide's Phase 3 trial in adults with type 2 diabetes — a study the site hasn't covered before and one that matters for anyone tracking the body-composition side of this drug class.
What happened
According to Lilly's announcement and trial coverage, a retatrutide symposium is scheduled for Saturday, June 6, 2026, 1:30–3:00 p.m. CDT, presenting results across two Phase 3 studies:
- TRANSCEND-T2D-1 (type 2 diabetes): retatrutide lowered A1C by up to an average of 2.0% and reduced weight by up to an average of 36.6 lbs (16.8%) at 40 weeks
- TRIUMPH-1 (obesity): participants lost up to an average of 70.3 lbs (28.3%) of body weight at 80 weeks
Retatrutide is described as a first-in-class triple receptor agonist, activating the receptors for glucose-dependent insulinotropic peptide (GIP), GLP-1, and glucagon at once. The diabetes numbers put it among the most potent agents in its category on both glycemic control and weight, in a population where losing fat while managing blood sugar is notoriously difficult.
We covered the obesity readout separately when TRIUMPH-1 reported its 80-week results; the diabetes trial is the new piece arriving at ADA.
Why it matters
For a strength-and-recovery audience, retatrutide sits in the same body-composition conversation as semaglutide, tirzepatide, and cagrilintide — powerful fat-loss tools whose catch is the same across the class: the weight comes off fast, and unless protein and resistance training are dialed in, some of it is muscle. The trials measure total weight and A1C, not lean-vs-fat composition in trained people, so the muscle-retention question we keep flagging — in our look at cagrilintide for body composition and keeping lean mass on a GLP-1 stack — applies here too.
The diabetes data also sharpens the comparison shoppers actually care about. With tirzepatide and semaglutide already established, retatrutide's pitch is more — more weight loss, more A1C reduction — and ADA is where that "more" gets scrutinized against the existing options rather than taken from a press release. Our tirzepatide vs semaglutide breakdown frames the trade-offs the triple agonist is trying to beat.
What to watch
The detail to watch from the June 6 session is the full safety and tolerability picture, not just the efficacy top line — GI side effects, discontinuation rates, and how the higher doses behaved. Also worth tracking: whether any DEXA or body-composition sub-analyses surface, since that's the data lifters need and the press releases never lead with. Retatrutide still has no FDA approval and remains in Phase 3, with regulatory filings expected later, so ADA is a readout milestone, not an availability one.
Sources
Sources